Feel Therapeutics, founded with a mission to revolutionize mental health care, focuses on developing digital biomarkers and therapeutics. Their vision is to bring objective data and measurement to the diagnosis, management, and care of mental health conditions. The company's product suite includes Feel 360º, Feel RxPal, Feel DTx, Feel Well, and Feel RPM, all integrated into their Digital Precision Medicine Platform. These solutions aim to provide comprehensive monitoring and personalized treatment options for mental health patients.
Notable investors in Feel Therapeutics include Felicis, Anthemis, and SOSV, underscoring significant confidence in their innovative approach. The company collaborates with major pharmaceutical firms to develop novel digital biomarkers. Key achievements include partnerships with leading healthcare and life science organizations, positioning Feel Therapeutics as a pioneer in the digital mental health space. Their impact is marked by the introduction of objective measurement tools in mental health care, promising more accurate diagnoses and effective treatments.
